Amgen (NASDAQ:AMGN) Issues FY 2026 Earnings Guidance

Amgen (NASDAQ:AMGN) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 21.600-23.000 for the period, compared to the consensus earnings per share estimate of 22.020. The company issued revenue guidance of $37.0 billion-$38.4 billion, compared to the consensus revenue estimate of $37.0 billion.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Oppenheimer set a $400.00 price target on Amgen and gave the stock an “outperform” rating in a report on Thursday, January 29th. Argus boosted their price objective on Amgen from $310.00 to $360.00 and gave the company a “buy” rating in a research report on Tuesday, December 30th. Piper Sandler raised their target price on shares of Amgen from $342.00 to $381.00 and gave the stock an “overweight” rating in a report on Friday, November 14th. Truist Financial lifted their price target on shares of Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a research note on Thursday, January 8th. Finally, Cantor Fitzgerald increased their price objective on shares of Amgen from $305.00 to $315.00 and gave the stock a “neutral” rating in a research report on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $342.45.

Amgen Stock Performance

Shares of Amgen stock traded down $6.09 during trading on Tuesday, hitting $338.59. 3,998,650 shares of the stock were exchanged, compared to its average volume of 2,674,891. The company has a current ratio of 1.28, a quick ratio of 0.99 and a debt-to-equity ratio of 5.45. The company has a fifty day moving average price of $332.81 and a 200-day moving average price of $309.74. The stock has a market capitalization of $182.32 billion, a price-to-earnings ratio of 26.17, a price-to-earnings-growth ratio of 3.02 and a beta of 0.46. Amgen has a 1-year low of $261.43 and a 1-year high of $353.25.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating analysts’ consensus estimates of $4.74 by $0.55. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The business had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities analysts predict that Amgen will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be given a $2.52 dividend. The ex-dividend date of this dividend is Friday, February 13th. This is a boost from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.0%. Amgen’s dividend payout ratio (DPR) is presently 73.57%.

Insiders Place Their Bets

In other Amgen news, EVP Murdo Gordon sold 6,879 shares of Amgen stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total value of $2,317,053.57. Following the completion of the transaction, the executive vice president directly owned 41,923 shares of the company’s stock, valued at $14,120,924.09. The trade was a 14.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Nancy A. Grygiel sold 3,139 shares of the stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the sale, the senior vice president directly owned 7,225 shares in the company, valued at approximately $2,436,703.50. This trade represents a 30.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 10,908 shares of company stock worth $3,674,966 in the last quarter. 0.69% of the stock is currently owned by corporate insiders.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q4 beat — Amgen reported EPS $5.29 vs. $4.74 consensus and revenue $9.87B vs. $9.46B; management cited higher drug sales and a lower tax rate as drivers. Amgen quarterly results beat Street estimates
• Positive Sentiment: Company releases — Full press release and investor slide deck available detailing results and product updates, useful for modeling near-term revenue and margin drivers. Amgen press release
• Positive Sentiment: Positive market commentary — Jim Cramer highlighted Amgen’s strong pipeline following JPMorgan Healthcare takeaways, which can support investor confidence in growth prospects. Jim Cramer on Amgen
• Neutral Sentiment: Wall Street coverage — Recent pieces assess whether analysts remain bullish or bearish; watch for updated analyst commentary and any changes to guidance or model assumptions. Amgen Stock: Is Wall Street Bullish or Bearish?
• Neutral Sentiment: MariTide focus — Analyst previews note that progress on MariTide and other pipeline milestones will be keys for investors going forward. Amgen Q4 preview
• Neutral Sentiment: Market data oddity — Reported short-interest update shows implausible zero figures (likely data error); not a meaningful market signal.
• Negative Sentiment: Collaboration setback — Amgen ended its Kyowa Kirin collaboration on rocatinlimab; analysts are reassessing valuation and potential future revenue from that program, which may be weighing on the stock. Assessing Amgen valuation after ending Kyowa Kirin collaboration

Hedge Funds Weigh In On Amgen

Hedge funds have recently bought and sold shares of the company. Brighton Jones LLC lifted its holdings in shares of Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after purchasing an additional 5,226 shares during the period. Schnieders Capital Management LLC. increased its stake in shares of Amgen by 29.3% in the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock valued at $7,220,000 after buying an additional 5,853 shares during the period. Sivia Capital Partners LLC boosted its holdings in Amgen by 10.6% in the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after acquiring an additional 114 shares during the last quarter. American Trust acquired a new stake in Amgen during the 3rd quarter valued at approximately $243,000. Finally, Clark Capital Management Group Inc. raised its holdings in Amgen by 19.8% during the 3rd quarter. Clark Capital Management Group Inc. now owns 1,103 shares of the medical research company’s stock worth $311,000 after purchasing an additional 182 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.